img
Mutahadithun EXCLUSIVE

Dr Shrooq Alsenan

AI in Healthcare & Drug Discovery

Dr Shrooq Alsenan

Biography

Dr. Shrooq A. Alsenan, a distinguished academic and researcher in Artificial Intelligence, currently directs the AI Center at Princess Nourah bint Abdulrahman University in Riyadh. With a Ph.D. in Information Systems Sciences from King Saud University, Dr. Alsenan has garnered multiple accolades, including the prestigious Jameel Clinic AI and Healthcare lab postdoctoral fellowship at MIT. Her research expertise spans AI in healthcare, including innovative AI bias detection methods and genetic analysis for transplant outcomes. Dr. Alsenan has held significant positions such as the head of research collaborations at PNU and has contributed extensively to the field with publications in high-impact journals. A committed educator, she has also been involved in various professional development programs at Harvard and holds certifications from institutions like Huawei and Microsoft. As an active member of the scientific community, Dr. Alsenan serves on review committees for several renowned journals and is a noted speaker on topics like AI in healthcare, leadership in technology, and data-driven decision making.

Dr Shrooq Alsenan

Featured Reviews

Dr Shrooq Alsenan

Featured Articles & Resources

img
Dr Shrooq Alsenan

AI in Healthcare & Drug Discovery

Computational approaches for synthesizing new chemical compounds have resulted in a major explosion of chemical data in the field of drug discovery. The quantitative structure-activity relationship (QSAR) is a widely used classification and regression method used to represent the relationship between a chemical structure and its activities. This research focuses on the effect of dimensionality-reduction techniques on a high-dimensional QSAR dataset. Because of the multi-dimensional nature of QSAR, dimensionality-reduction techniques have become an integral part of its modeling process. Principal component analysis (PCA) is a feature extraction technique with several applications in exploratory data analysis, visualization, and dimensionality reduction. However, linear PCA is inadequate to handle the complex structure of QSAR data. In light of the wide array of current feature-extraction techniques, we …

img
Dr Shrooq Alsenan

AI in Healthcare & Drug Discovery

The blood–brain barrier plays a crucial role in regulating the passage of 98% of the compounds that enter the central nervous system (CNS). Compounds with high permeability must be identified to enable the synthesis of brain medications for the treatment of various brain diseases, such as Parkinson’s, Alzheimer’s, and brain tumors. Throughout the years, several models have been developed to solve this problem and have achieved acceptable accuracy scores in predicting compounds that penetrate the blood–brain barrier. However, predicting compounds with “low” permeability has been a challenging task. In this study, we present a deep learning (DL) classification model to predict blood–brain barrier permeability. The proposed model addresses the fundamental issues presented in former models: high dimensionality, class imbalances, and low specificity scores. We address these issues to enhance the high-dimensional, imbalanced dataset before developing the classification model: the imbalanced dataset is addressed using oversampling techniques and the high dimensionality using a non-linear dimensionality reduction technique known as kernel principal component analysis (KPCA). This technique transforms the high-dimensional dataset into a low-dimensional Euclidean space while retaining invaluable information. For the classification task, we developed an enhanced feed-forward deep learning model and a convolutional neural network model. In terms of specificity scores (ie, predicting compounds with low permeability), the results obtained by the enhanced feed-forward deep learning model outperformed those obtained by …

img
Dr Shrooq Alsenan

AI in Healthcare & Drug Discovery

The rapid development of computational methods and the increasing volume of chemical and biological data have contributed to an immense growth in chemical research. This field of study is known as “chemoinformatics,” which is a discipline that uses machine-learning techniques to extract, process, and extrapolate data from chemical structures. One of the significant lines of research in chemoinformatics is the study of blood–brain barrier (BBB) permeability, which aims to identify drug penetration into the central nervous system (CNS). In this research, we attempt to solve the problem of BBB permeability by predicting compounds penetration to the CNS. To accomplish this goal: (i) First, an overview is provided to the field of chemoinformatics, its definition, applications, and challenges, (ii) Second, a broad view is taken to investigate previous machine-learning and deep-learning computational models to solve BBB …